Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 1, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,850,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,466.787 pence per share.
- Treasury Shares Held: 122,233,000 shares following the transaction.
- Shares in Issue: 5,825,878,471 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed this purchase on November 1, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the share count (1,850,000) by the price (1,466.787 pence).
- Confirm the updated total share capital structure (5,825,878,471 issued shares plus 122,233,000 treasury shares).
- Review the original shareholder authorization from the May 25, 2005 Annual General Meeting to understand the full scope of the buyback program.